QLS32015 not checked

Qilu Pharmaceutical

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Relapsed or Refractory Multiple Myeloma (2 trials)
Main trialPhase 3
“The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.”In the company’s words, NCT07138209 on ClinicalTrials.gov

Other drugs for Relapsed or Refractory Multiple Myeloma

All 266 drugs for Relapsed or Refractory Multiple Myeloma

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Dec 2027 A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2Recruiting Nov 2027 Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Phase 1Unknown 31 Dec 2024 A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow QLS32015

Following is part of Solo: you see every change to QLS32015 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in